Apeiron has granted GSK exclusive rights to its APN01 enzyme, in phase I development to treat Acute Respiratory Distress Syndrome
Apeiron Biologics has granted GlaxoSmithKline(GSK) exclusive rights to the Austrian company's APN01 enzyme, currently in phase I development to treat Acute Respiratory Distress Syndrome (ARDS).
The deal will see GSK pay Apeiron an up-front payment of
